Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Building publication competence: Insights from the "JPGM Conference 2025".

Journal of postgraduate medicine·2026
Same author

From bedside to journal: Writing high-quality case reports.

Journal of postgraduate medicine·2026
Same author

JPGM: Editor's report (2024-2025).

Journal of postgraduate medicine·2025
Same author

Mediastinal mass in an infant: A rare presentation of extrapulmonary tuberculosis.

Journal of postgraduate medicine·2025
Same author

Authors, beware of plagiarism in medical writing.

Journal of postgraduate medicine·2025
Same author

A new editorial team takes over….

Journal of postgraduate medicine·2024
Same journal

Assessment of exclusive breastfeeding practices in a tribal district of Maharashtra: A cross-sectional study.

Journal of postgraduate medicine·2026
Same journal

Leveraging immersive technology with virtual emulation for training of nonmedico combatants: A randomized controlled trial.

Journal of postgraduate medicine·2026
Same journal

From clinic to microscope: A study of clinicopathological concordance in 5000 skin biopsies from a tertiary care center.

Journal of postgraduate medicine·2026
Same journal

Early anticoagulation with warfarin for pulmonary embolism complicating active gastric ulcer: A case against guideline-mandated delay.

Journal of postgraduate medicine·2026
Same journal

Paradoxical Hemophagocytic Lymphohistiocytosis to Stevens-Johnson Syndrome - Toxic Epidermal Necrolysis- A rare immune phenomenon.

Journal of postgraduate medicine·2026
Same journal

Anesthetic management of neonate with hypoplastic left heart syndrome posted for exploratory laparotomy.

Journal of postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

Oseltamivir.

M S Tullu1

  • 1Department of Pediatrics, Seth GS Medical College and KEM Hospital, Mumbai, India. milindtullu@vsnl.net

Journal of Postgraduate Medicine
|November 4, 2009
PubMed
Summary
This summary is machine-generated.

Oseltamivir effectively treats and prevents influenza infections by inhibiting neuraminidase. Early treatment offers greater benefits, though drug resistance is a potential future concern.

More Related Videos

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
09:04

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

Related Experiment Videos

Last Updated: Jun 19, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
09:04

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation

Published on: September 7, 2010

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Oseltamivir is a neuraminidase inhibitor crucial for managing Influenza A (H1N1).
  • It is a primary therapeutic agent against novel influenza strains, indicated for uncomplicated influenza infections.

Purpose of the Study:

  • To review the efficacy, pharmacokinetics, and safety of oseltamivir.
  • To outline treatment and prophylaxis guidelines for oseltamivir.

Main Methods:

  • Review of oseltamivir's mechanism of action as a neuraminidase enzyme inhibitor.
  • Analysis of pharmacokinetic data including absorption, metabolism to oseltamivir carboxylate, and urinary elimination.
  • Summary of clinical data on treatment and prophylaxis, including dosing, adverse effects, and drug interactions.

Main Results:

  • Oseltamivir is well-absorbed and converted to its active metabolite, oseltamivir carboxylate.
  • The drug is generally well-tolerated, with nausea and vomiting as common side effects.
  • Standard adult doses are 75 mg twice daily for treatment and 75 mg once daily for prophylaxis, with renal dose adjustments needed.

Conclusions:

  • Early oseltamivir initiation maximizes clinical benefits for influenza treatment and prophylaxis.
  • Oseltamivir is generally safe with few drug interactions, but renal impairment requires dose adjustment.
  • Potential development of drug resistance necessitates ongoing monitoring of influenza virus susceptibility.